TrialCancer science2014

Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.

Akihiko Gemma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.